妇科肿瘤患者科研活检的患者报告结局、认知与意愿
该前瞻性研究纳入2015—2019年Princess Margaret癌症中心接受科研活检的妇科恶性肿瘤患者,用活检前后问卷评估焦虑、症状与再次活检意愿。129例入组、91例(70.5%)完成至少1份问卷;活检后焦虑抑郁量表总分较活检前下降,84%表示肯定或可能同意再次活检。
要点
- 活检总体接受度较好,84%(58/69)愿再次活检。
- 疼痛(60.3%)与身体不适(61.8%)为常见体验。
- 身体不适、尴尬、失去尊严及活检后流感样症状降低再次活检意愿。
核心结论
- 科研活检总体被妇科肿瘤患者较好接受,多数患者愿必要时接受多次活检。
- 处理可改变的心理社会因素可能改善科研活检体验。
研究设计与样本
- 前瞻性研究,2015—2019年在Princess Margaret癌症中心开展(NCT02334761)。
- 入组接受科研活检的妇科恶性肿瘤患者129例,91例(70.5%)完成至少1份问卷。
- 活检前及活检后1周发放纸质问卷,采用改良版医院焦虑抑郁量表评估焦虑。
主要发现
- 卵巢癌占89%(81/91),子宫内膜癌占11%(10/91);75%活检取自腹部或盆腔(67/89)。
- 临床医生报告1例并发症,为肝周血肿(1%)。
- 活检时疼痛60.3%(41/68)、身体不适61.8%(42/68)、尴尬13.2%(9/68)、失去尊严11.8%(8/68)。
- 焦虑抑郁量表总分活检前5.3(标准差4.7)降至活检后3.7(标准差4.5),P=.005。
- 84%(58/69)表示肯定或可能同意再次活检。
关键数值与推荐
- 身体不适(OR 0.14,P=.005)、尴尬(OR 0.03,P=.004)、失去尊严(OR 0.05,P=.01)者再次活检意愿更低。
- 活检后1周流感样症状(OR 0.2,P=.018)或发热感(OR 0.2,P=.035)者再次活检意愿更低。
- 活检前量表评分较高(OR 0.83,P=.008)及活检后评分较高(OR 0.8,P=.003)者再次活检意愿更低。
- ECOG状态、活检部位、年龄、穿刺针数及活检时疼痛与再次活检意愿无关。
临床怎么用
- 向患者说明科研活检常见疼痛与身体不适,并主动询问尴尬、尊严等心理社会感受。
- 对活检前焦虑评分较高或活检后出现流感样症状者,提前沟通再次活检的必要性与支持措施。
局限性
- 仅91/129例(70.5%)完成至少1份问卷,存在失访与报告偏倚可能。
- 单中心研究,以卵巢癌患者为主,外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite the growing integration of mandatory biopsies for correlative endpoints within oncology clinical trials, there are sparse data on patient-reported outcomes, perceptions, and preferences. OBJECTIVE: This study aimed to prospectively assess the impact of research biopsies on the quality of life in patients with gynecologic cancer, evaluate patient-reported outcomes, and determine factors associated with patients' willingness to undergo sequential biopsies. STUDY DESIGN: We conducted a prospective study in patients with gynecologic malignancies undergoing research biopsies between 2015 and 2019 at Princess Margaret Cancer Centre (ClinicalTrials.gov Identifier: NCT02334761). Here, we report the results of the paper-based surveys performed before and 1 week after biopsy. Although the questionnaires each assessed the impact of anxiety using a modified version of the Hospital Anxiety and Depression Scale, the postbiopsy questionnaire specifically assessed the likelihood of future biopsies, postbiopsy symptoms, complications, and perceptions. RESULTS: A total of 129 patients were enrolled, of which 91 (70.5%) completed at least 1 questionnaire. These patients had either ovarian (89%; 81 of 91) or endometrial cancer (11%; 10 of 91). Of all biopsies taken, 75% were from the abdomen or pelvis (67 of 89). There was 1 clinician-reported complication, a perihepatic hematoma (1%). Pain during the biopsy and physical discomfort were experienced by 60.3% (41 of 68) and 61.8% (42 of 68), respectively. Embarrassment and loss of dignity were experienced by 13.2% (9 of 68) and 11.8% (8 of 68), respectively. Although the mean Hospital Anxiety and Depression Scale score was in the normal range before and after biopsy, there was a significant decline in the total score after the biopsy (prebiopsy, 5.3 [standard deviation, 4.7] vs postbiopsy, 3.7 [standard deviation, 4.5]; P=.005); 84% of subjects (58 of 69) stated that they would definitely or likely consent to another biopsy. There was no impact on patients' willingness for future biopsies based on Eastern Cooperative Oncology Group status, biopsy site, age, number of cores, and pain during the biopsy; however, subjects who reported feeling physically uncomfortable (odds ratio, 0.14; P=.005), embarrassed (odds ratio, 0.03; P=.004) or experienced loss of dignity (odds ratio, 0.05; P=.01) during the biopsy and those who experienced flu-like symptoms (odds ratio, 0.2; P=.018) or felt feverish (odds ratio, 0.2; P=.035) 1 week after biopsy, were less likely to undergo a sequential biopsy. Similarly, those with higher Hospital Anxiety and Depression Scale scores before biopsy (odds ratio, 0.83; P=.008) and after biopsy (odds ratio, 0.8; P=.003) were less likely to consent for another biopsy. CONCLUSION: Research biopsies were generally well accepted. Most patients (83%) were willing to undergo serial biopsies if necessary. Addressing the potentially modifiable psychosocial aspects of the procedure may improve the experience with research biopsies for patients with gynecologic cancers.
引用
- Madariaga A, Bhat G, Wilson MK, et al. Research biopsies in patients with gynecologic cancers: patient-reported outcomes, perceptions, and preferences. Am J Obstet Gynecol. 2021. PMID: 34174204. doi:10.1016/j.ajog.2021.06.071
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。